Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A proof-of-concept clinical trial of BLU-554 in combination with CS1001 as a first-line treatment in patients with hepatocellular carcinoma in China

Trial Profile

A proof-of-concept clinical trial of BLU-554 in combination with CS1001 as a first-line treatment in patients with hepatocellular carcinoma in China

Recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Jan 2019

At a glance

  • Drugs BLU 554 (Primary) ; CS 1001 (Primary)
  • Indications Liver cancer
  • Focus Proof of concept; Therapeutic Use
  • Most Recent Events

    • 28 Jan 2019 According to Blueprint Medicines media release, the National Medical Products Administration (NMPA) has approved the clinical trial application (CTA) to start this trial in China for BLU-554 (CS3008). The company expects to begin enrolment soon.
    • 28 Jan 2019 Status changed from planning to recruiting, according to Blueprint Medicines media release.
    • 04 Jan 2019 According to Blueprint Medicines media release, this trial is expected to initiate in the second half of 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top